{"id":1856,"date":"2025-12-17T13:07:32","date_gmt":"2025-12-17T13:07:32","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T13:07:32","modified_gmt":"2026-06-26T13:07:32","slug":"therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses","status":"publish","type":"post","link":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/","title":{"rendered":"Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li>L&#8217;\u00e9tude a d\u00e9montr\u00e9 un engagement clair de la cible aux deux doses test\u00e9es\u00a0<\/li>\n\n\n\n<li>Potentiel du THRV-1268 pour traiter la QTcF prolong\u00e9e dans les maladies cardiom\u00e9taboliques\u00a0<\/li>\n\n\n\n<li>L&#8217;\u00e9tude Phase 2a Aspire-HF d\u00e9butera en 2026\u00a0<\/li>\n<\/ul>\n\n\n\n<p><strong>Montr\u00e9al, Qu\u00e9bec<\/strong>&nbsp;<strong>\u2013 17 d\u00e9cembre 2025&nbsp;<\/strong>\u2013 Th\u00e9rapeutiques Thryv Inc., une soci\u00e9t\u00e9 de biotechnologie en phase clinique pionni\u00e8re dans le d\u00e9veloppement de nouveaux inhibiteurs de la s\u00e9rum glucocortico\u00efde-inductible kinase 1 (SGK1) pour le traitement des arythmies cardiaques h\u00e9r\u00e9ditaires, des maladies cardiom\u00e9taboliques et des cardiomyopathies, a annonc\u00e9 aujourd&#8217;hui des r\u00e9sultats encourageants d&#8217;une \u00e9tude clinique de phase 1 r\u00e9cemment achev\u00e9e \u00e9valuant le THRV-1268 chez des participants ob\u00e8ses (NCT07186946).&nbsp;<\/p>\n\n\n\n<p>Dans une cohorte d\u00e9di\u00e9e de participants ob\u00e8ses (IMC&gt;30 kg\/m2), les individus ont montr\u00e9 un raccourcissement absolu et corrig\u00e9 par placebo de la QTcF \u00e0 partir de la ligne de base apr\u00e8s une seule dose de THRV-1268. Ce jeu de donn\u00e9es important soutient le profil \u00e9lectrophysiologique diff\u00e9renci\u00e9 du compos\u00e9 dans des conditions pertinentes pour les maladies cardiom\u00e9taboliques (incluant augmentation du poids corporel et de l&#8217;indice de masse corporelle).&nbsp;<\/p>\n\n\n\n<p>L&#8217;\u00e9tude a \u00e9valu\u00e9 la pharmacodynamique, la pharmacocin\u00e9tique, la s\u00e9curit\u00e9 et la tol\u00e9rabilit\u00e9 du THRV-1268 \u00e0 deux doses croissantes simples chez des participants ob\u00e8ses. Le THRV-1268 semblait bien tol\u00e9r\u00e9 sans qu&#8217;aucun effet ind\u00e9sirable grave n&#8217;ait \u00e9t\u00e9 signal\u00e9. La pharmacocin\u00e9tique a d\u00e9montr\u00e9 que les expositions th\u00e9rapeutiques \u00e9taient maintenues tout au long de l&#8217;intervalle de dosage et soutenaient une dose deux fois par jour.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<p>L&#8217;\u00e9tude comprenait une \u00e9valuation comparative de la biodisponibilit\u00e9 \u00e9valuant une nouvelle formulation en comprim\u00e9 de THRV-1268. Les r\u00e9sultats ont d\u00e9montr\u00e9 des profils pharmacocin\u00e9tiques \u00e9quivalents entre le comprim\u00e9 et la suspension orale.&nbsp; D&#8217;apr\u00e8s les donn\u00e9es de cette \u00e9tude, des ajustements de dose bas\u00e9s sur le poids ne sont pas pr\u00e9vus pour le prochain essai clinique de phase 2a ASPIRE sur l&#8217;insuffisance cardiaque.&nbsp;<\/p>\n\n\n\n<p><strong>Dur\u00e9e du QTc et risque clinique en cas d&#8217;insuffisance cardiaque<\/strong>&nbsp;<\/p>\n\n\n\n<p>La dur\u00e9e du QTc \u00e0 l&#8217;\u00e9lectrocardiogramme est de plus en plus reconnue comme un marqueur de la gravit\u00e9 de la maladie et du risque de mort subite cardiaque en cas d&#8217;insuffisance cardiaque. D&#8217;apr\u00e8s son m\u00e9canisme d&#8217;action, l&#8217;inhibition de SGK1 avec THRV-1268 repr\u00e9sente une approche th\u00e9rapeutique novatrice avec le potentiel de traiter \u00e0 la fois le remodelage \u00e9lectrique et structurel en cas d&#8217;insuffisance cardiaque. Des \u00e9tudes observationnelles ont montr\u00e9 que des intervalles QTc prolong\u00e9s sont plus fr\u00e9quents chez les patients souffrant d&#8217;insuffisance cardiaque avanc\u00e9e que chez ceux atteints de maladie plus l\u00e9g\u00e8re. Chez les patients pr\u00e9sentant une insuffisance cardiaque plus s\u00e9v\u00e8re (BNP &gt;400 pg\/mL), environ 50 % pr\u00e9sentent une prolongation du QTc (&gt;440 ms). Dans cette population, il a \u00e9t\u00e9 d\u00e9montr\u00e9 que le QTc prolong\u00e9 peut pr\u00e9dire de mani\u00e8re ind\u00e9pendante les cons\u00e9quences ind\u00e9sirables, notamment des taux plus \u00e9lev\u00e9s de mortalit\u00e9 toutes causes confondues, de mort subite cardiaque et de d\u00e9c\u00e8s par d\u00e9faillance de pompe.&nbsp;<\/p>\n\n\n\n<p>Th\u00e9rapeutiques Thryv pr\u00e9voit d&#8217;initier ASPIRE-HF, un essai clinique de phase 2a, en 2026, afin d&#8217;\u00e9valuer le THRV-1268 chez des patients pr\u00e9sentant une insuffisance cardiaque symptomatique avec fraction d&#8217;\u00e9jection r\u00e9duite (HFrEF) et un intervalle QT prolong\u00e9.&nbsp;&nbsp;<\/p>\n\n\n\n<p><strong>\u00c0 propos de Th\u00e9rapeutiques Thryv<\/strong>&nbsp;<\/p>\n\n\n\n<p>Th\u00e9rapeutiques Thryv Inc. est une soci\u00e9t\u00e9 priv\u00e9e bas\u00e9e \u00e0 Montr\u00e9al, Qu\u00e9bec, Canada. Thryv est \u00e0 la pointe d\u2019une approche de m\u00e9decine de pr\u00e9cision visant \u00e0 traiter les canalopathies g\u00e9n\u00e9tiques, les maladies cardiom\u00e9taboliques et les cardiomyopathies gr\u00e2ce \u00e0 des inhibiteurs puissants et s\u00e9lectifs de s\u00e9rum glucocortico\u00efde-inductible kinase 1 (SGK1). Pour plus d&#8217;informations, veuillez visiter le site&nbsp;<a href=\"http:\/\/www.thryvtrx.ca\/\" target=\"_blank\" rel=\"noreferrer noopener\">www.thryvtrx.ca<\/a>.&nbsp;&nbsp;<\/p>\n\n\n\n<p><strong>Demandes des m\u00e9dias<\/strong>&nbsp;<\/p>\n\n\n\n<p><a href=\"mailto:brittany@thryvtrx.com?\" target=\"_blank\" rel=\"noreferrer noopener\">brittany@thryvtrx.com<\/a>&nbsp;| 514 973 0915&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/thryvtrx.ca\/fr\/nouvelles\/phase-1-thrv-1268\">Lire le communiqu\u00e9 original<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Montr\u00e9al, Qu\u00e9bec&nbsp;\u2013 17 d\u00e9cembre 2025&nbsp;\u2013 Th\u00e9rapeutiques Thryv Inc., une soci\u00e9t\u00e9 de biotechnologie en phase clinique pionni\u00e8re dans le d\u00e9veloppement de nouveaux inhibiteurs de la s\u00e9rum glucocortico\u00efde-inductible kinase 1 (SGK1) pour [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1878,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"company":[124],"class_list":["post-1856","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-des-compagnies-du-portefeuille"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses | adMare\" \/>\n<meta property=\"og:description\" content=\"Montr\u00e9al, Qu\u00e9bec&nbsp;\u2013 17 d\u00e9cembre 2025&nbsp;\u2013 Th\u00e9rapeutiques Thryv Inc., une soci\u00e9t\u00e9 de biotechnologie en phase clinique pionni\u00e8re dans le d\u00e9veloppement de nouveaux inhibiteurs de la s\u00e9rum glucocortico\u00efde-inductible kinase 1 (SGK1) pour [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-17T13:07:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T13:07:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1199\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses\",\"datePublished\":\"2025-12-17T13:07:32+00:00\",\"dateModified\":\"2026-06-26T13:07:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\\\/\"},\"wordCount\":697,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/thryv-therapeutics-fr-1-1758136900.png\",\"articleSection\":[\"Actualit\u00e9s des compagnies du portefeuille\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\\\/\",\"name\":\"Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/thryv-therapeutics-fr-1-1758136900.png\",\"datePublished\":\"2025-12-17T13:07:32+00:00\",\"dateModified\":\"2026-06-26T13:07:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/thryv-therapeutics-fr-1-1758136900.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/thryv-therapeutics-fr-1-1758136900.png\",\"width\":1199,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses | adMare","og_description":"Montr\u00e9al, Qu\u00e9bec&nbsp;\u2013 17 d\u00e9cembre 2025&nbsp;\u2013 Th\u00e9rapeutiques Thryv Inc., une soci\u00e9t\u00e9 de biotechnologie en phase clinique pionni\u00e8re dans le d\u00e9veloppement de nouveaux inhibiteurs de la s\u00e9rum glucocortico\u00efde-inductible kinase 1 (SGK1) pour [&hellip;]","og_url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/","og_site_name":"adMare","article_published_time":"2025-12-17T13:07:32+00:00","article_modified_time":"2026-06-26T13:07:32+00:00","og_image":[{"width":1199,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses","datePublished":"2025-12-17T13:07:32+00:00","dateModified":"2026-06-26T13:07:32+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/"},"wordCount":697,"publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png","articleSection":["Actualit\u00e9s des compagnies du portefeuille"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/","url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/","name":"Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png","datePublished":"2025-12-17T13:07:32+00:00","dateModified":"2026-06-26T13:07:32+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png","width":1199,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/fr\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/fr\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/fr\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/fr\/#website","url":"https:\/\/admarebio.com\/fr\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/fr\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1856","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/comments?post=1856"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1856\/revisions"}],"predecessor-version":[{"id":1857,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1856\/revisions\/1857"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media\/1878"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media?parent=1856"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/categories?post=1856"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/tags?post=1856"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/company?post=1856"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}